The effect of myoinositol on ovarian blood flows in women with polycystic ovary syndrome
| Autor: | Özlen Emekçi Özay, Recep Emre Okyay, Bülent Gülekli, Ali Cenk Ozay |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Adult
medicine.medical_specialty Stromal cell Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism Ethinyl Estradiol 03 medical and health sciences Young Adult 0302 clinical medicine Endocrinology Internal medicine medicine Humans Ultrasonography Doppler Color 030219 obstetrics & reproductive medicine business.industry Ovary Obstetrics and Gynecology Blood flow Color doppler Polycystic ovary Folic acid Regional Blood Flow Female business Inositol Polycystic Ovary Syndrome |
| Popis: | To evaluate whether 4 gram myoinositol and 400 mcg folic acid(MYO) therapy has any effects on ovarian stromal blood flow by using pulsed and color Doppler at 3 months follow-up period in polycystic ovary syndrome (PCOS). One-hundred eighty patients were designed into six groups; Group 1: PCOS patients that received OCP containing 30 mcg ethinyl estradiol (EE) plus 3 mg drospirenone (DRP); Group 2: PCOS patients that received MYO; Group 3: PCOS patients that received no medication. Group 4: Healthy patients that received OCP; Group 5: Healthy patients that received MYO; Group 6: Healthy patients that received no medication. Resistance index (RI) and pulsatility index (PI) of both ovaries were assessed. There was a significant increase in RI and PI of both ovarian stromal blood flow women with PCOS who received OCP (Group 1, p < .001) and MYO (Group 2, p < .001). The rate of increment in both RI and PI values were similar for OCP users (Group 1) and MYO users(Group2) in PCOS patients. MYO therapy reduced ovarian vascularization in both PCOS and healthy users after 3 months and this decrease is especially noticeable in women with PCOS compared to healthy women. OCP therapy also reduced ovarian vascularization just like MYO therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|